Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations

This systematic review and meta-analysis evaluated the impact of targeted therapies on lipid profiles in patients with psoriasis or psoriatic arthritis. The study encompassed 24,575 individuals receiving various biologics and small-molecule inhibitors, including Janus kinase inhibitors, tumor necrosis factor alpha inhibitors, interleukin-17 A inhibitors, and IL-23p19 inhibitors. The analysis focused on short- and long-term follow-up periods to assess changes in total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Results indicated that these treatments do not have a uniform effect on lipid metabolism, highlighting the need for careful patient selection and monitoring.

Specific findings demonstrated that certain interventions significantly increased total cholesterol, with a weighted mean difference of 7.03 mg/dL. Similarly, triglyceride levels rose substantially in some cohorts, showing a weighted mean difference of 19.98 mg/dL. High-density lipoprotein cholesterol also increased in several instances, suggesting a complex modulation of lipid fractions rather than a simple global elevation or reduction. Conversely, other treatment arms exhibited significant decreases in these markers, with total cholesterol dropping by 8.40 mg/dL in specific subgroups. These divergent outcomes underscore the heterogeneity of drug classes and their distinct metabolic signatures.

The study also noted that low-density lipoprotein cholesterol levels were significantly altered, either increasing or decreasing depending on the specific agent used. In some cases, LDL cholesterol rose by 12.37 mg/dL, while in others, it fell by 10.61 mg/dL. This variability challenges the assumption that all biologics share identical metabolic side effect profiles. Clinicians must therefore consider the specific mechanism of action and class of inhibitor when managing patients with concurrent cardiovascular risk factors. The data suggests that while some therapies may exacerbate dyslipidemia, others might offer neutral or even beneficial effects on lipid parameters.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported in the available literature for this specific analysis. This lack of detailed safety reporting limits the ability to fully contextualize the lipid findings within a broader clinical safety framework. Nevertheless, the practice relevance emphasizes the necessity of routine lipid monitoring during TNF-alpha and JAK-targeted therapy. Healthcare providers should establish baseline lipid profiles before initiating treatment and schedule periodic reassessments to detect unfavorable shifts early. This proactive approach aligns with broader guidelines for managing cardiovascular risk in patients with inflammatory skin diseases.

Limitations of the current analysis include the reliance on observational studies and the absence of extended follow-up periods in many included trials. Well-designed prospective studies with longer observation windows are warranted to validate and refine these observations. Furthermore, the inability to infer causation from within-group pre-to-post changes in observational studies necessitates cautious interpretation of the results. Clinicians should avoid assuming specific drug names beyond the classes listed and recognize that individual patient responses may vary significantly. Future research should aim to clarify the mechanisms driving these lipid alterations and identify patient subgroups most susceptible to metabolic changes.

In conclusion, this meta-analysis provides critical insights into the metabolic effects of targeted therapies for psoriasis and psoriatic arthritis. The findings highlight the importance of personalized medicine approaches, where lipid profiles are considered alongside disease activity and treatment efficacy. By understanding the potential for both increases and decreases in lipid markers, clinicians can better counsel patients and optimize therapeutic strategies. Routine monitoring remains essential to mitigate cardiovascular risks associated with certain agents while leveraging the benefits of others. Continued investigation into the long-term metabolic consequences of these drugs will further inform clinical decision-making and improve patient outcomes.